Journal of Alzheimer's disease : JAD · 2026
Drebrin is a novel biomarker of cognitive deterioration in Alzheimer's disease.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shoji Mikio, Kawarabayashi Takeshi, Nakamura Takumi, Sugawara Takashi, Ishizawa Kunihiko, Amari Masakuni, Takahashi Ryoma, Kasahara Hiroo, Koganezawa Noriko, Higa Ayaka, Takatama Masamitsu, Ikeda Yoshio, Sekino Yuko, Shirao Tomoaki
Аннотация
BackgroundThe cerebrospinal fluid (CSF) and plasma amyloid-β (Aβ)40/42 ratio, p-217tau and p-181tau, and neurofilament light chain are biomarkers of Aβ proteinopathy, tau proteinopathy, and neuronal injury, respectively, in Alzheimer's disease (AD). However, direct biomarkers of cognitive function have yet to be identified.ObjectiveTherefore, the present study investigated the potential of CSF and plasma levels of drebrin, a postsynaptic protein, as biomarkers of synaptic activity and cognitive function in the human brain in clinical settings.MethodsWe developed a novel ELISA to measure CSF and plasma levels of drebrin and analyzed 68 CSF and 128 plasma samples from patients with AD and other neurological diseases.ResultsCSF drebrin levels were significantly reduced in samples of mild cognitive impairment due to AD, the dementia stages of AD, and idiopathic normal pressure hydrocephalus. Plasma drebrin levels were also significantly reduced in samples of MCI due to AD.ConclusionsCSF and plasma drebrin levels are specific biomarkers of cognitive decline in the MCI stage of AD.